Skip to content
SABSSAB Biotherapeutics, Inc.

Earnings

When SAB Biotherapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

23 quarters. Mar 31, 2021 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

10-K due Mar 26 – Apr 5

No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 6 filings.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 26 – Apr 5

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q4 2024 −62.4%, Q3 2024 −100.0%, Q2 2024 +207.7%, Q1 2024 +62.5%
Net income
-$16.86M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q4 2024 · derived$114.70K−62.4% vs Q4 2023

Latest results

  1. Q3 2026Nov 5, 2026, before the open
    Revenue
    —
    —
    Net income
    -$22.30M
    N/M
    EPS
    -$0.24
    N/M
  2. Q2 2026Aug 6, 2026, before the open+2.7%by the close of Aug 6
    Revenue
    —
    —
    Net income
    -$22.49M
    N/M
    EPS
    -$0.28
    N/M
  3. Q1 2026May 12, 2026, before the open2.7%by the close of May 12
    Revenue
    —
    —
    Net income
    -$18.87M
    N/M
    EPS
    -$0.35
    N/M
  4. Q4 2025Mar 9, 2026, after the close+6.8%by the close of Mar 10
    Revenue
    —
    —
    Net income
    -$16.86M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026—Nov 5, 202636 d10-Q——-$0.24—
Q2 2026Jun 30, 2026—Aug 6, 202637 d10-Q——-$0.28+2.7%
Q1 2026Mar 31, 2026—May 12, 202642 d10-Q——-$0.352.7%
FY 2025
Q4 2025derivedDec 31, 2025—Mar 9, 202668 d10-K———+6.8%
Q3 2025Sep 30, 2025—Nov 14, 202545 d10-Q——-$0.21+3.8%
Q2 2025Jun 30, 2025—Aug 7, 202538 d10-Q——-$1.090.2%
Q1 2025Mar 31, 2025—May 9, 202539 d10-Q——-$0.56+2.3%
FY 2024
Q4 2024derivedDec 31, 2024—Mar 31, 202590 d10-K$114.70K−62.4%—11.7%
Q3 2024Sep 30, 2024—Nov 6, 202437 d10-Q$0.00−100.0%-$1.1215.3%
Q2 2024Jun 30, 2024—Aug 8, 202439 d10-Q$263.14K+207.7%-$0.7913.1%
Q1 2024Mar 31, 2024—May 20, 202450 d10-Q$944.58K+62.5%-$0.54—
Earlier years, FY 2021 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 5, 2026448600
10-QAug 6, 2026336783
10-QMay 12, 2026218195
10-KMar 9, 2026000003
10-QNov 14, 2025280572
10-QAug 7, 2025104566
10-QMay 9, 2025067554
10-KMar 31, 2025046994
10-QNov 6, 2024122443
10-QAug 8, 2024094084

Provenance

ProvenanceData status and checks

SAB Biotherapeutics, Inc. · CIK 1833214 · Engraved from SEC EDGAR